CROI 2016 Program at a Glance

Program and Agenda

Session P-E3 Poster Abstracts

Hall A/B

Session P-F4 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM Evaluating HIV Vaccines: Preclinical to Clinical 317 Immunogenicity and Efficacy of ALVAC-HIV/gp120- Clade C in Alum Regimen in Macaques Luca Schifanella 1 ; DavidVenzon 1 ; Susan Barnett 2 ; Sanjay Phogat 3 ; GeorgiaTomaras 4 ; David Montefiori 4 ; Massimiliano Bissa 1 ;Veronica Galli 1 ; Ruth M. Ruprecht 5 ; Genoveffa Franchini 1 1 NIH,Bethesda,MD,USA; 2 Novartis,Cambridge,MA,USA; 3 Sanofi, Swiftwater,PA,USA; 4 DukeUniv,Durham,NC,USA; 5 TexasBiomedRsr Inst,SanAntonio,TX,USA 318 Specific IgG Subclasses Induced in RV305, a Late Boost Vaccination of RV144 Subjects Siriwat Akapirat 1 ; SandhyaVasan 2 ; Punnee Pitisuttithum 3 ; Supachai Rerks-Ngarm 4 ; Nelson L. Michael 5 ; Jean-Louis Excler 6 ; Jerome H. Kim 7 ; Robert O’Connell 1 ; Nicos Karasavvas 1 ; for the RV305 Study Group 1 ArmedForcesRsr InstofMedScis,Bangkok,Thailand; 2 USMilitaryHIV RsrProg,APO,AP,USA; 3 MahidolUniv,Ratchathewi,Thailand; 4 Ministry ofPH,MuangNonthaburi,Thailand; 5 USMilitaryHIVRsrProg,Bethesda, MD,USA; 6 HenryM. JacksonFndn for theAdvancementofMilitaryMed, Inc,Bethesda,MD,USA; 7 IntlVaccine Inst,Seoul,RepublicofKorea 319 Vaccine Targeting Protease Cleavage Sites Protects Cynomolgus Monkeys Against SIV Ma Luo 1 ; DavidTang 1 ; Rupert Capina 1 ; Xin-YongYuan 1 ; Jorge Correia-Pinto 2 1 NatlMicrobiologyLabofCanada,Winnipeg,MB,Canada; 2 Univof SantiagodeCompostela,SantiagodeCompostela,Spain 320 Shaping CTL ImmunodominanceWith Conserved HIV Vaccines After Early Treatment (BCN01) Beatriz Mothe 1 ; Christian Manzardo 2 ; Pep Coll 1 ; Sara Moron-Lopez 1 ; Lucy Dorrell 3 ; Bonaventura Clotet 4 ; Javier Martinez-Picado 1 ; Christian Brander 1 ;Tomá Hanke 5 ; for the BCN01 Study Group 1 IrsiCaixa Inst forAIDSRsr,Badalona,Spain; 2 HospClinic-IDIBAPS-Univ ofBarcelona,Barcelona,Spain; 3 UnivofOxford,Oxford,UK; 4 LluitaContra laSIDAFndn,GermansTrias iPujolUnivHosp,Barcelona,Spain; 5 The Jenner Inst,Oxford,UK 321 DNA/rTV/Protein Vaccination Protects Against Acquisition of SHIV162P3 Challenges Xuan He ; Zhou Zhang;Ying Liu;Yanling Hao; Li Ren; Kunxue Hong; Yiming Shao NatlCntr forAIDS/STDControlandPrevention,ChineseCDC,Beijing, China 322 Poly-ICLC, a TLR Agonist, Is Safe and Tolerable in HIV-Infected Individuals Elizabeth A. Miller 1 ; Rachel Sabado 1 ; Andres Salazar 2 ; Melissa LaMar 3 ; Martin Markowitz; Nina Bhardwaj 1 1 IcahnSchofMedatMountSinai,NewYork,NY,USA; 2 Oncovir, Inc, Washington,DC,USA; 3 AaronDiamondAidsRsrCntr,NewYork,NY,USA 323 TLR-9 Signaling Rescues Defects in B-Cell Response in Needle-Free Immunization Prabhu S Arunachalam 1 ; Ria Mishra 1 ; Sravan Payeli 2 ; Deepak Selvam 1 ; Richard R. Stout 3 ; Udaykumar Ranga 1

2:45 PM-4:00 PM Impact of Antiretroviral Therapy on Viremic Control and Tissue Reservoirs 346 Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials Graham C.Treasure 1 ; Evgenia Aga 2 ; Ronald Bosch 2 ; JohnW. Mellors 3 ; Daniel Kuritzkes 4 ; RajeshT. Gandhi 5 ; Michael Para 6 ; Jonathan Z. Li 1 1 BrighamandWomen’sHosp,HarvardMedSch,Boston,MA,USA; 2 HarvardSchofPH,Boston,MA,USA; 3 UnivofPittsburgh,Pittsburgh,PA, USA; 4 HarvardMedSch,Boston,MA,USA; 5 MassachusettsGeneralHosp, Boston,MA,USA; 6 OhioStateUniv,Columbus,OH,USA Behzad Etemad 1 ; Xiaoming Sun 2 ; Michael M. Lederman 3 ; Rachel Z. Gottlieb 1 ; Evgenia Aga 4 ; Ronald Bosch 4 ; Jeffrey Jacobson 5 ; RajeshT. Gandhi 6 ; Xu G.Yu 2 ; Jonathan Z. Li 1 1 BrighamandWomen’sHosp,HarvardMedSch,Boston,MA,USA; 2 Ragon InstofMGH,MIT,andHarvard,Cambridge,MA,USA; 3 Case WesternReserveUniv,Cleveland,OH,USA; 4 HarvardSchofPH,Boston, MA,USA; 5 DrexelUnivCollofMed,Philadelphia,PA,USA; 6 Massachusetts GeneralHosp,Boston,MA,USA AnniWinckelmann 1 ; Kirston Barton 2 ; Bonnie Hiener 2 ;Thomas A. Rasmussen 3 ; MartinTolstrup 1 ;Wei Shao 4 ; PaulW. Denton 1 ; Sharon R. Lewin 3 ; Ole S. Søgaard 1 ; Sarah Palmer 2 1 AarhusUnivHosp,AarhusNord,Denmark; 2 Cntr forVirusRsr,Westmead Millennium Inst,Westmead,Australia; 3 Doherty Inst for Infectionand Immunity,UnivofMelbourne,Melbourne,Australia; 4 LeidosBiomedRsr, Inc,Frederick,MD,USA 349 HIV DNA Set Point Remains Elevated in Untreated vs Treated Acutely Infected Thais Jintanat Ananworanich 1 ; Nicolas Chomont 2 ; Leigh . Eller 3 ; Eugène Kroon 4 ; Meera Bose 3 ; Marty Nau 3 ; Suteeraporn Pinyakorn 3 ; Nelson L. Michael 5 ; Nittaya Phanuphak 4 ; Merlin L. Robb 3 ; for the RV254/ SEARCH010 study groups 1 MilitaryHIVRsrProg,Bethesda,MD,USA; 2 UnivdeMontréal,Montreal, QC,Canada; 3 USMilitaryHIVRsrProg,WalterReedArmy InstofRsr, SilverSpring,MD,USA; 4 SEARCH,Bangkok,Thailand; 5 USMilitaryHIVRsr Prog,Bethesda,MD,USA 350 Impact of Long-term Antiretroviral Therapy (ART) on Cellular HIV and Inflammation RajeshT. Gandhi 1 ; Deborah McMahon 2 ; Ronald Bosch 3 ; Christina Lalama 3 ; Josh Cyktor 2 ; Bernard J. Macatangay 4 ; Charles Rinaldo 2 ; Ann Collier 5 ; Joseph J. Eron 6 ; JohnW. Mellors 2 1 MassachusettsGeneralHosp,Boston,MA,USA; 2 UnivofPittsburgh, Pittsburgh,PA,USA; 3 HarvardSchofPH,Boston,MA,USA; 4 Univof PittsburghSchofMed,Pittsburgh,PA,USA; 5 UnivofWashington,Seattle, WA,USA; 6 UnivofNorthCarolinaatChapelHill,ChapelHill,NC,USA 347 Viral and Immune Characteristics of HIV Post- Treatment Controllers in ACTG Studies 348 HIV-1 in the Blood and Intestine Contributes to Viremia During Treatment Interruption

Poster Listings

1 JawaharlalNehruCntr forAdvancedScientificRsr,Bangalore, India; 2 BmomFertilityandRsrCntr,Bangalore, India; 3 BiojectMed Technologies, Inc,Tigard,OR,USA

82

CROI 2016